{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:56:46Z","timestamp":1771653406945,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Center of the Portuguese Oncology Institute of Porto","award":["CI-IPOP 4-2012"],"award-info":[{"award-number":["CI-IPOP 4-2012"]}]},{"name":"Research Center of the Portuguese Oncology Institute of Porto","award":["CI-IPOP-17-2015"],"award-info":[{"award-number":["CI-IPOP-17-2015"]}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CM1406"],"award-info":[{"award-number":["CM1406"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/71293\/2010"],"award-info":[{"award-number":["SFRH\/BD\/71293\/2010"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/112673\/2015"],"award-info":[{"award-number":["SFRH\/BD\/112673\/2015"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011929","name":"Programa Operacional Tem\u00e1tico Factores de Competitividade","doi-asserted-by":"crossref","award":["CI-IPOP-BPD\/UID\/DTP\/00776\/2013"],"award-info":[{"award-number":["CI-IPOP-BPD\/UID\/DTP\/00776\/2013"]}],"id":[{"id":"10.13039\/501100011929","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12935-019-0835-9","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T13:29:58Z","timestamp":1556544598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Histone variant MacroH2A1 is downregulated in prostate cancer and influences malignant cell phenotype"],"prefix":"10.1186","volume":"19","author":[{"given":"T\u00e2nia Soraia","family":"Vieira-Silva","sequence":"first","affiliation":[]},{"given":"Sara","family":"Monteiro-Reis","sequence":"additional","affiliation":[]},{"given":"Daniela","family":"Barros-Silva","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Ramalho-Carvalho","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Gra\u00e7a","sequence":"additional","affiliation":[]},{"given":"Isa","family":"Carneiro","sequence":"additional","affiliation":[]},{"given":"Ana Teresa","family":"Martins","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Luis","family":"Antunes","sequence":"additional","affiliation":[]},{"given":"Sarah","family":"Hurtado-Bag\u00e8s","sequence":"additional","affiliation":[]},{"given":"Marcus","family":"Buschbeck","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,4,29]]},"reference":[{"key":"835_CR1","first-page":"25","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:25.","journal-title":"CA Cancer J Clin"},{"issue":"18","key":"835_CR2","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1101\/gad.1965810","volume":"24","author":"MM Shen","year":"2010","unstructured":"Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010;24(18):1967\u20132000.","journal-title":"Genes Dev"},{"issue":"4","key":"835_CR3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.eururo.2011.06.035","volume":"60","author":"C Jeronimo","year":"2011","unstructured":"Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol. 2011;60(4):753\u201366.","journal-title":"Eur Urol"},{"issue":"3","key":"835_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00018-013-1343-z","volume":"71","author":"C Vardabasso","year":"2014","unstructured":"Vardabasso C, Hasson D, Ratnakumar K, Chung CY, Duarte LF, Bernstein E. Histone variants: emerging players in cancer biology. Cell Mol Life Sci. 2014;71(3):379\u2013404.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"835_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00441-014-1862-4","volume":"356","author":"B Biterge","year":"2014","unstructured":"Biterge B, Schneider R. Histone variants: key players of chromatin. Cell Tissue Res. 2014;356(3):457\u201366.","journal-title":"Cell Tissue Res"},{"issue":"8\u201314","key":"835_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.gde.2014.03.001","volume":"25","author":"C Volle","year":"2014","unstructured":"Volle C, Dalal Y. Histone variants: the tricksters of the chromatin world. Curr Opin Genet Dev. 2014;25(8\u201314):138.","journal-title":"Curr Opin Genet Dev"},{"issue":"11","key":"835_CR7","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.18632\/oncotarget.2007","volume":"5","author":"FL Monteiro","year":"2014","unstructured":"Monteiro FL, Baptista T, Amado F, Vitorino R, Jer\u00f3nimo C, Helguero LA. Expression and functionality of histone H2A variants in cancer. Oncotarget. 2014;5(11):3428\u201343.","journal-title":"Oncotarget."},{"key":"835_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1101\/gad.1272805","volume":"19","author":"RT Kamakaka","year":"2005","unstructured":"Kamakaka RT, Biggins S. Histone variants: deviants? Genes Dev. 2005;19:295\u2013310.","journal-title":"Genes Dev"},{"issue":"6685","key":"835_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/31275","volume":"393","author":"C Costanzi","year":"1998","unstructured":"Costanzi C, Pehrson JR. Histone MacroH2A1 is concentrated in the inactive X chromosome of female mammals. Nature. 1998;393(6685):599\u2013601.","journal-title":"Nature"},{"issue":"10","key":"835_CR10","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/nsmb.1665","volume":"16","author":"M Buschbeck","year":"2009","unstructured":"Buschbeck M, Uribesalgo I, Wibowo I, Rue P, Martin D, Gutierrez A, et al. The histone variant MacroH2A is an epigenetic regulator of key developmental genes. Nat Struct Mol Biol. 2009;16(10):1074\u20139.","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"835_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1101\/gad.1876110","volume":"24","author":"MJ Gamble","year":"2010","unstructured":"Gamble MJ, Frizzell KM, Yang C, Krishnakumar R, Kraus WL. The histone variant MacroH2A1 marks repressed autosomal chromatin, but protects a subset of its target genes from silencing. Genes Dev. 2010;24(1):21\u201332.","journal-title":"Genes Dev"},{"issue":"3","key":"835_CR12","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/0008-5472.CAN-15-1336","volume":"76","author":"M Borghesan","year":"2016","unstructured":"Borghesan M, Fusilli C, Rappa F, Panebianco C, Rizzo G, Oben JA, et al. DNA Hypomethylation and histone variant MacroH2A1 synergistically attenuate chemotherapy-induced senescence to promote hepatocellular carcinoma progression. Cancer Res. 2016;76(3):594\u2013606.","journal-title":"Cancer Res"},{"issue":"5","key":"835_CR13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.molcel.2015.07.011","volume":"59","author":"H Chen","year":"2015","unstructured":"Chen H, Ruiz PD, McKimpson WM, Novikov L, Kitsis RN, Gamble MJ. MacroH2A1 and ATM play opposing roles in paracrine senescence and the senescence-associated secretory phenotype. Mol Cell. 2015;59(5):719\u201331.","journal-title":"Mol Cell"},{"issue":"1","key":"835_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.devcel.2004.10.019","volume":"8","author":"R Zhang","year":"2005","unstructured":"Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, Daganzo SM, et al. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell. 2005;8(1):19\u201330.","journal-title":"Dev Cell"},{"issue":"13","key":"835_CR15","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.4161\/cc.9.13.12144","volume":"9","author":"MJ Gamble","year":"2014","unstructured":"Gamble MJ, Kraus WL. Multiple facets of the unique histone variant MacroH2A: from genomics to cell biology. Cell Cycle. 2014;9(13):2568\u201374.","journal-title":"Cell Cycle"},{"key":"835_CR16","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/ncomms2582","volume":"4","author":"A Gaspar-Maia","year":"2013","unstructured":"Gaspar-Maia A, Qadeer ZA, Hasson D, Ratnakumar K, Leu NA, Leroy G, et al. MacroH2A histone variants act as a barrier upon reprogramming towards pluripotency. Nat Commun. 2013;4:1565.","journal-title":"Nat Commun."},{"issue":"8","key":"835_CR17","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1128\/MCB.06323-11","volume":"32","author":"C Creppe","year":"2012","unstructured":"Creppe C, Janich P, Cantarino N, Noguera M, Valero V, Musulen E, et al. MacroH2A1 regulates the balance between self-renewal and differentiation commitment in embryonic and adult stem cells. Mol Cell Biol. 2012;32(8):1442\u201352.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"835_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.canlet.2013.03.022","volume":"336","author":"N Cantarino","year":"2013","unstructured":"Cantarino N, Douet J, Buschbeck M. MacroH2A\u2014an epigenetic regulator of cancer. Cancer Lett. 2013;336(2):247\u201352.","journal-title":"Cancer Lett"},{"issue":"11","key":"835_CR19","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/nsmb.2903","volume":"21","author":"H Chen","year":"2014","unstructured":"Chen H, Ruiz PD, Novikov L, Casill AD, Park JW, Gamble MJ. MacroH2A1.1 and PARP-1 cooperate to regulate transcription by promoting CBP-mediated H2B acetylation. Nat Struct Mol Biol. 2014;21(11):981\u20139.","journal-title":"Nat Struct Mol Biol."},{"issue":"Pt 24","key":"835_CR20","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.1242\/jcs.113019","volume":"125","author":"V Pasque","year":"2012","unstructured":"Pasque V, Radzisheuskaya A, Gillich A, Halley-Stott RP, Panamarova M, Zernicka-Goetz M, et al. Histone variant MacroH2A marks embryonic differentiation in vivo and acts as an epigenetic barrier to induced pluripotency. J Cell Sci. 2012;125(Pt 24):6094\u2013104.","journal-title":"J Cell Sci"},{"issue":"20","key":"835_CR21","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1128\/MCB.05244-11","volume":"31","author":"L Novikov","year":"2011","unstructured":"Novikov L, Park JW, Chen H, Klerman H, Jalloh AS, Gamble MJ. QKI-mediated alternative splicing of the histone variant MacroH2A1 regulates cancer cell proliferation. Mol Cell Biol. 2011;31(20):4244\u201355.","journal-title":"Mol Cell Biol"},{"issue":"11","key":"835_CR22","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/nsmb.2390","volume":"19","author":"E Dardenne","year":"2012","unstructured":"Dardenne E, Pierredon S, Driouch K, Gratadou L, Lacroix-Triki M, Espinoza MP, et al. Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness. Nat Struct Mol Biol. 2012;19(11):1139\u201346.","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"835_CR23","doi-asserted-by":"publisher","first-page":"e98930","DOI":"10.1371\/journal.pone.0098930","volume":"9","author":"AC Lavigne","year":"2014","unstructured":"Lavigne AC, Castells M, Mermet J, Kocanova S, Dalvai M, Bystricky K. Increased MacroH2A1.1 expression correlates with poor survival of triple-negative breast cancer patients. PLoS ONE. 2014;9(6):e98930.","journal-title":"PLoS ONE."},{"issue":"7327","key":"835_CR24","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/nature09590","volume":"468","author":"A Kapoor","year":"2010","unstructured":"Kapoor A, Goldberg MS, Cumberland LK, Ratnakumar K, Segura MF, Emanuel PO, et al. The histone variant MacroH2A suppresses melanoma progression through regulation of CDK8. Nature. 2010;468(7327):1105\u20139.","journal-title":"Nature"},{"issue":"38","key":"835_CR25","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1038\/onc.2009.26","volume":"28","author":"JC Sporn","year":"2009","unstructured":"Sporn JC, Kustatscher G, Hothorn T, Collado M, Serrano M, Muley T, et al. Histone MacroH2A isoforms predict the risk of lung cancer recurrence. Oncogene. 2009;28(38):3423\u20138.","journal-title":"Oncogene"},{"issue":"6","key":"835_CR26","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1016\/j.ajpath.2012.02.027","volume":"180","author":"JC Sporn","year":"2012","unstructured":"Sporn JC, Jung B. Differential regulation and predictive potential of MacroH2A1 isoforms in colon cancer. Am J Pathol. 2012;180(6):2516\u201326.","journal-title":"Am J Pathol"},{"issue":"3","key":"835_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/cancers10030059","volume":"10","author":"D Corujo","year":"2018","unstructured":"Corujo D, Buschbeck M. Post-translational modifications of H2A histone variants and their role in cancer. Cancers. 2018;10(3):59.","journal-title":"Cancers."},{"issue":"10","key":"835_CR28","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.18632\/oncotarget.1237","volume":"4","author":"T Baptista","year":"2013","unstructured":"Baptista T, Gra\u00e7a I, Sousa EJ, et al. Regulation of histone H2A.Z expression is mediated by sirtuin 1 in prostate cancer. Oncotarget. 2013;4(10):1673\u201385.","journal-title":"Oncotarget."},{"issue":"4","key":"835_CR29","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1093\/nar\/gkq994","volume":"39","author":"M Barzily-Rokni","year":"2011","unstructured":"Barzily-Rokni M, Friedman N, Ron-Bigger S, Isaac S, Michlin D, Eden A. Synergism between DNA methylation and MacroH2A1 occupancy in epigenetic silencing of the tumor suppressor gene p16(CDKN2A). Nucleic Acids Res. 2011;39(4):1326\u201335.","journal-title":"Nucleic Acids Res"},{"key":"835_CR30","volume-title":"Pathology and genetics of tumours of the urinary system and male genital organs","author":"JN Eble","year":"2004","unstructured":"Eble JN, Organization WH, Cancer IAfRo. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004."},{"issue":"1","key":"835_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","volume":"143","author":"JA Hanley","year":"1982","unstructured":"Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29\u201336.","journal-title":"Radiology"},{"issue":"10","key":"835_CR32","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/onc.2015.187","volume":"35","author":"SJ Park","year":"2015","unstructured":"Park SJ, Shim JW, Park HS, et al. MacroH2A1 downregulation enhances the stem-like properties of bladder cancer cells by transactivation of Lin28B. Oncogene. 2015;35(10):1292\u2013301.","journal-title":"Oncogene."},{"key":"835_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0356-3","author":"JM Kim","year":"2018","unstructured":"Kim JM, Shin Y, Lee S, et al. MacroH2A1.2 inhibits prostate cancer-induced osteoclastogenesis through cooperation with HP1\u03b1 and H1.2. Oncogene. 2018;. \n                    https:\/\/doi.org\/10.1038\/s41388-018-0356-3\n                    \n                  .","journal-title":"Oncogene."},{"issue":"16","key":"835_CR34","doi-asserted-by":"publisher","first-page":"7572","DOI":"10.1158\/0008-5472.CAN-06-4652","volume":"67","author":"S Shin","year":"2007","unstructured":"Shin S, Rossow KL, Grande JP, Janknecht R. Involvement of RNA helicases p68 and p72 in colon cancer. Cancer Res. 2007;67(16):7572\u20138.","journal-title":"Cancer Res"},{"issue":"19","key":"835_CR35","doi-asserted-by":"publisher","first-page":"7938","DOI":"10.1158\/0008-5472.CAN-08-0932","volume":"68","author":"EL Clark","year":"2008","unstructured":"Clark EL, Coulson A, Dalgliesh C, Rajan P, Nicol SM, Fleming S, et al. The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res. 2008;68(19):7938\u201346.","journal-title":"Cancer Res"},{"issue":"1","key":"835_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4161\/rna.23312","volume":"10","author":"FV Fuller-Pace","year":"2013","unstructured":"Fuller-Pace FV. DEAD box RNA helicase functions in cancer. RNA Biol. 2013;10(1):121\u201332.","journal-title":"RNA Biol"},{"issue":"12","key":"835_CR37","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1111\/j.1464-410X.2011.10628.x","volume":"109","author":"BB McGuire","year":"2012","unstructured":"McGuire BB, Helfand BT, Loeb S, Hu Q, O\u2019Brien D, Cooper P, et al. Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level. BJU Int. 2012;109(12):1764\u20139.","journal-title":"BJU Int."},{"key":"835_CR38","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fgene.2018.00417","volume":"9","author":"S Hurtado-Bages","year":"2018","unstructured":"Hurtado-Bages S, Guberovic I, Buschbeck M. The MacroH2A11\u2013PARP1 axis at the intersection between stress response and metabolism. Front Genet. 2018;9:417.","journal-title":"Front Genet"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-019-0835-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12935-019-0835-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-019-0835-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T23:06:04Z","timestamp":1588028764000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-019-0835-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,29]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["835"],"URL":"https:\/\/doi.org\/10.1186\/s12935-019-0835-9","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,29]]},"assertion":[{"value":"16 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"112"}}